As is the case with other chronic illnesses, having polycystic kidney disease may make you feel overwhelmed. But you don't have to deal with your illness alone. The support of friends and family is important in dealing with a chronic illness. In addition, a counselor, psychologist, psychiatrist or clergy member may be able to help.
You may also want to consider joining a support group. Although support groups aren't for everyone, they can provide helpful information about treatments and coping. And being with people who understand what you're going through may make you feel less alone.
Ask your doctor about support groups in your community or contact the PKD Foundation at 800-PKD-CURE (800-753-2873) to find out if there's a chapter in your area.
June 14, 2014
- Polycystic kidney disease. National Kidney and Urologic Diseases Information Clearinghouse. http://kidney.niddk.nih.gov/kudiseases/pubs/polycystic/. Accessed March 29, 2014.
- Ferri FF. Ferri's Clinical Advisor 2014: 5 Books in 1. Philadelphia, Pa.: Mosby Elsevier; 2014. https://www.clinicalkey.com. Accessed March 29, 2014.
- Alpern RJ, et al. Seldin and Giebisch's The Kidney. 5th ed. Philadelphia, Pa.: Elsevier; 2013. http://www.clinicalkey.com. Accessed March 29, 2014.
- Polycystic kidney disease. Kidney Foundation. http://www.kidney.org/atoz/content/polycystic.cfm . Accessed March 29, 2014.
- Taal MW, et al. Brenner & Rector's The Kidney. 9th ed. Philadelphia, Pa.: Saunders Elsevier; 2011. http://www.clinicalkey.com. Accessed March 29, 2014.
- Riggin EA. Decision Support System. Mayo Clinic, Rochester, Minn. Feb. 26, 2014.
- Devuyst O, et al. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease. Current Opinion in Nephrology and Hypertension. 2013;22:459.
- Rossetti S, et al. Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. Journal of the American Society of Nephrology. 2012;23:915.
- Torres VE, et al. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. Journal of the American Society of Nephrology. 2014; 25:18.
- Torres VE, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. New England Journal of Medicine. 2012;367:2407.
- Hogan MC, et al. Somatostatin analog therapy for severe polycystic liver disease: Results after 2 years. Nephrology Dialysis Transplantation. 2012;27:3532.
- Castle EP (expert opinion). Mayo Clinic, Phoenix /Scottsdale, Ariz. April 6, 2014.
- Heilman RL (expert opinion). Mayo Clinic, Phoenix/Scottsdale, Ariz. April 7, 2014.